Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Adjuvant treatment for breast cancer

Flatley MJ. and Dodwell DJ., (2019), Surgery (United Kingdom)

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM. et al, (2018), Eur J Cancer, 101, 210 - 219

Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery?

Bagenal J. et al, (2018), BMJ, 361

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.

Maxwell AJ. et al, (2018), Eur J Surg Oncol, 44, 429 - 435

Neoadjuvant chemotherapy for early breast cancer - Author's reply.

McGale P. et al, (2018), Lancet Oncol, 19

A longitudinal cohort study to identify risk factors for the development of invasive cancer in unresected DCIS

Maxwell AJ. et al, (2018), CANCER RESEARCH, 78

Impact of radiotherapy and endocrine therapy on further events: Final multivariate analysis of a prospective, national cohort study of screen detected ductal carcinoma in situ (DCIS) of the breast

Thompson AM. et al, (2018), CANCER RESEARCH, 78

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2018), Lancet Oncol, 19, 27 - 39

Making progress in early breast cancer: Taking time or accepting risk?

Mannu GS. and Dodwell D., (2017), Eur J Cancer, 78, 24 - 27

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

Taylor C. et al, (2017), J Clin Oncol, 35, 1641 - 1649

Doing More With Less; Are There Some ‘Easy Wins’ in the Management of Early Breast Cancer?

Dodwell DJ. et al, (2017), Clinical Oncology

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.

Wallington M. et al, (2016), Lancet Oncol, 17, 1203 - 1216

The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project.

Maxwell AJ. et al, (2016), Breast, 27, 109 - 115

Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS)

Thompson AM. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P. et al, (2016), Ann Oncol, 27, 379 - 390

Adjuvant treatment for breast cancer

Flatley MJ. and Dodwell DJ., (2016), Surgery (United Kingdom), 34, 43 - 46

POSNOC: Positive sentinel node-Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: A randomised trial looking at axillary treatment in early breast cancer (ISRCTN54765244).

Goyal A. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33

The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ

Francis A. et al, (2013), CANCER RESEARCH, 73

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Johnston SR. et al, (2013), Lancet Oncol, 14, 989 - 998

Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects.

Marshall H. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30

Load More

Include forthcoming?